Use of Remdesivir in children with COVID-19: report of an Italian multicenter study
ConclusionOur experience indicates that RDV against SARS-CoV-2 is safe and well-tolerated in pediatric populations at high risk of developing severe COVID-19. Our data suggest that delaying RDV therapy after diagnosis of pneumonia may be associated with a longer duration of antiviral therapy, especially in patients with comorbidities.
Source: Italian Journal of Pediatrics - Category: Pediatrics Source Type: research
More News: Antiviral Therapy | Children | Clinical Trials | Cough | COVID-19 | Eating Disorders & Weight Management | Italy Health | Obesity | Pediatrics | Pneumonia | SARS | Study